In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Alimera Sciences, Inc.. Trade Record

NASDAQ:ALIM Alimera Sciences, Inc. stock gains 20.06% Exit Jul 26, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ALIM Jun 26, 2018, priceSeries
About Alimera Sciences, Inc.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Trade Information
Trade Type
LONG
ReliabilityScore™
97.17
Entry Date
Jun 26, 2018
Entry Price
0.90
Sell Date
Jul 26, 2018
Sell Price
1.08
Net Gain
20.06%
Hold Time
21 Trading Days